Brian Till, MD

Title(s)Resident Physician, Surgery
SchoolSchool of Medicine
Address35 Medical Center Way, #902D
San Francisco CA 94143
vCardDownload vCard

    Collapse Bibliographic 
    Collapse publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia. Blood Adv. 2026 09 22; 10(18):6291-6298. Wu X, Shadman M, Voutsinas J, Hippe DS, Randolph TW, Ujjani CS, Crider C, Keshmiri S, Smith SD, Lynch RC, Di M, Huang JJ, Martin PS, Till BG, Gopal AK. PMID: 42466974; PMCID: PMC13594711.
      View in: PubMed   Mentions:    Fields:    
    2. Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma. J Clin Oncol. 2026 Sep 20; 44(27):2625-2633. Lynch RC, Poh C, Shadman M, Till BG, Di M, Ujjani CS, Raghunathan V, Smith SD, Maloney D, Gausman D, Rasmussen H, Russler-Germain DA, Fehniger TA, Kurtz DM, Alizadeh A, Voutsinas J, Gopal AK. PMID: 42600120.
      View in: PubMed   Mentions:
    3. Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma. Blood Adv. 2026 May 26; 10(10):3565-3571. Baek G, Varma G, Yamshon S, van Besien H, Bartlett NL, Watkins M, Shah HR, Baron K, Merryman RW, Falade AS, Svoboda J, Prischak S, D'Angelo C, Lukowski JD, Advani RH, Yeung AH, Rosenberg M, Voutsinas J, Di M, Lynch R, Poh C, Raghunathan V, Shadman M, Smith S, Till BG, Ujjani C, Diefenbach CS, Gopal AK. PMID: 41855500; PMCID: PMC13196555.
      View in: PubMed   Mentions:    Fields:    
    4. Combined Heart-Liver Transplant in a Patient With End-Stage Liver Disease and Contained Rupture of an Aortic Root Pseudoaneurysm. Ann Thorac Surg. 2026 May 12. Miller PN, Till B, Fiedler AG. PMID: 42128127.
      View in: PubMed   Mentions:    Fields:    
    5. CD20-Targeted α-Radionuclides Synergize with Immune Checkpoint Inhibition to Treat Murine Lymphoma. J Nucl Med. 2026 05 01; 67(5):693-699. O'Steen S, Lee SY, Comstock ML, Kehret AR, Lin Y, Hamlin DK, Dexter SL, Hippe DS, Gooley TA, Wilbur DS, Li Y, Walter RB, Till B, Orozco JJ, Green DJ. PMID: 41644291; PMCID: PMC13138093.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    6. Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response. Nat Commun. 2026 Apr 07; 17(1). Ozog S, Krantz EM, Tindbaek K, Munoz J, Liu WL, Chalal C, Pernikoff S, Yahya K, Stevens-Ayers T, Dasgupta S, Cowan AJ, Green DJ, Gauthier J, Till BG, Gardner RA, Shadman M, Bleakley M, Boeckh M, Boonyaratanakornkit J, Turtle CJ, Hill JA. PMID: 41942445; PMCID: PMC13234265.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    7. Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based Models. JCO Clin Cancer Inform. 2026 01; 10:e2500148. Liang EC, Jeon Y, Qiao Y, Wu X, Huang JJ, Portuguese AJ, Basom R, Torkelson A, Kirchmeier D, Braathen K, Cowan AJ, Shadman M, Hirayama AV, Till BG, Kimble EL, Wu Q, Gauthier J. PMID: 41534004; PMCID: PMC12810859.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    8. Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2026 Mar; 26(3):e367-e375. Ho C, Kennedy N, Di M, Gopal AK, Lynch RC, Ng K, Wu QV, Poh C, Raghunathan V, Rasmussen H, Shadman M, Till BG, Ujjani CS, Smith SD. PMID: 41285650.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia. Br J Haematol. 2025 Nov; 207(5):2143-2146. Poh C, Chen X, Voutsinas J, Naresh K, Dizon JJ, Shadman M, Lynch RC, Till BG, Ujjani CS, Di M, Raghunathan V, Warren EH, Smith SD, Wu QV, Cherian S, Gopal AK. PMID: 40931545.
      View in: PubMed   Mentions: 1     Fields:    
    10. Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials. Transplant Cell Ther. 2025 Dec; 31(12):1002.e1-1002.e9. Portuguese AJ, Tuazon SA, Pont MJ, Cole GO, Sather BD, Song X, Thomas S, Wood BL, Blake M, Works MG, Shadman M, Liang EC, Wu VQ, Voutsinas JM, Gooley TA, Turtle CJ, Till BG, Coffey DG, Maloney DG, Libby EN, Chapuis AG, Milano F, Riddell SR, Green DJ, Cowan AJ. PMID: 40930223.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    11. Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas. Blood Adv. 2025 Aug 12; 9(15):4037-4042. Poh C, Voutsinas JM, Shadman M, Lynch RC, Warren EH, Crimp CA, Till BG, Ujjani CS, Di M, Raghunathan V, Smith SD, Wu QV, Shinohara MM, Gopal AK. PMID: 40526835; PMCID: PMC12345251.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma. Br J Haematol. 2025 Oct; 207(4):1599-1603. Lynch RC, Cassaday RD, Smith SD, Cowan AJ, Warren EH, Shadman MS, Till BG, Ujjani CS, Morris K, Rasmussen H, Voutsinas J, Gopal AK. PMID: 41070684.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    13. A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up. Blood. 2025 Jul 31; 146(5):535-545. Tuazon SA, Portuguese AJ, Pont MJ, Cowan AJ, Cole GO, Sather BD, Song X, Thomas S, Wood BL, Blake M, Works MG, Shadman M, Liang EC, Wu QV, Voutsinas JM, Gooley TA, Turtle CJ, Till BG, Coffey DG, Maloney DG, Riddell SR, Green DJ. PMID: 40198877; PMCID: PMC12782959.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    14. Opportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell Therapy. Transplant Cell Ther. 2025 Oct; 31(10):838.e1-838.e16. Ng SK, Flaherty PW, Ancheta M, Tindbaek KA, Sekhon MK, Huang JJ, Portuguese AJ, Albittar A, Kopmar NE, Cowan AJ, Shadman M, Hirayama AV, Till BG, Cassaday RD, Turtle CJ, Liu C, Xie H, Leisenring WM, Gauthier J, Liang EC, Hill JA. PMID: 40752589.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma. Blood. 2025 Jun 05; 145(23):2762-2767. Samples L, Sadrzadeh H, Frigault MJ, Jacobson CA, Hamadani M, Gurumurthi A, Strati P, Shouval R, Noy A, Riedell PA, Dahiya S, Maloney DG, Till BG, Hirayama AV, Gauthier J, Gopal AK, Smith SD, Poh C, Lynch R, Ujjani C, Di M, Raghunathan V, Shakib-Azar M, Naresh KN, Gooley TA, Yared J, Jain MD, Locke FL, Leslie LA, Epperla N, Ghosh M, Skarbnik A, Hill BT, Kamdar MK, Ortiz-Maldonado V, Martinez-Cibrian N, Shune L, Shadman M. PMID: 39938007.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    16. Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow-up. Haematologica. 2025 09 01; 110(9):2040-2054. Portuguese AJ, Huang JJ, Jeon Y, Taheri M, Albittar A, Liang EC, Hirayama AV, Kimble EL, Iovino L, Poh C, Gopal AK, Shadman M, Till BG, Milano F, Chapuis AG, Otegbeye F, Cassaday RD, Basom RS, Wu QV, Maloney DG, Gauthier J. PMID: 40079097; PMCID: PMC12399936.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    17. Development and validation of predictive models of early immune effector cell-associated hematotoxicity. Blood Adv. 2025 Feb 11; 9(3):606-616. Liang EC, Huang JJ, Portuguese AJ, Ortiz-Maldonado V, Albittar A, Wuliji N, Basom R, Jeon Y, Wu Q, Torkelson A, Kirchmeier D, Chutnik A, Pender B, Sorror M, Hill JA, Kopmar NE, Banerjee R, Cowan AJ, Green D, Gopal AK, Poh C, Shadman M, Hirayama AV, Till BG, Kimble EL, Iovino L, Chapuis AG, Otegbeye F, Cassaday RD, Milano F, Turtle CJ, Maloney DG, Gauthier J. PMID: 39626349; PMCID: PMC11847049.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    18. Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World Experience. JCO Oncol Pract. 2025 May; 21(5):671-676. Huang IJ, Baek GT, Cohen J, Khajaviyan S, Louie S, Samples L, Smith SD, Till BG, Warren EH, Gopal AK, Poh C, Lynch RC, Ujjani CS, Shadman M. PMID: 39556786.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation. Blood. 2024 09 05; 144(10):1069-1082. Krakow EF, Brault M, Summers C, Cunningham TM, Biernacki MA, Black RG, Woodward KB, Vartanian N, Kanaan SB, Yeh AC, Dossa RG, Bar M, Cassaday RD, Dahlberg A, Till BG, Denker AE, Yeung CCS, Gooley TA, Maloney DG, Riddell SR, Greenberg PD, Chapuis AG, Newell EW, Furlan SN, Bleakley M. PMID: 38683966; PMCID: PMC11406181.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    20. Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL. Blood. 2024 09 05; 144(10):1083-1092. Smith MR, Jegede OA, Martin P, Till BG, Parekh SS, Yang DT, Hsi ED, Witzig T, Dave S, Scott D, Hanson C, Kostakoglu Shields L, Abdel-Samad N, Casulo C, Bartlett NL, Caimi PF, Al Baghdadi T, Blum KA, Romer MD, Inwards DJ, Lerner RE, Wagner LI, Little RF, Friedberg JW, Leonard JP, Kahl BS. PMID: 38820500; PMCID: PMC11561533.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    21. Erratum to: Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies. Haematologica. 2024 07 01; 109(7):2378. Woolston DW, Lee ND, Shadman M, Latorre-Esteves E, Tee XR, Fredrickson J, Kohrn BF, Ujjani C, Eckel A, Till B, Fang M, Radich J, Bozic I, Risques RA, Yeung CCS. PMID: 38946649; PMCID: PMC11215368.
      View in: PubMed   Mentions:    Fields:    
    22. Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor-Adoptive T-cell Therapy. Blood Cancer Discov. 2024 Jul 01; 5(4):258-266. Mo G, Lee SY, Coffey DG, Voillet V, Kirsch IR, Gottardo R, Smythe KS, Yeung CCS, Greenbaum A, Green DJ, Maloney DG, Till BG. PMID: 38747505; PMCID: PMC11215399.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    23. Impact and Durability of the Affordable Care Act Medicaid Expansion on Lung Cancer Treatment. Ann Thorac Surg Short Rep. 2024 Dec; 2(4):895-900. Thosani DS, Till BM, Meredith LT, Kalra A, Barta JA, Okusanya OT, Evans NR, Grenda TR. PMID: 39790601; PMCID: PMC11708614.
      View in: PubMed   Mentions:
    24. Association Between Utilization of Services and Perioperative Outcomes for Lung Cancer Resection. Clin Lung Cancer. 2024 Nov; 25(7):e330-e336. Thosani DS, Meredith LT, West R, Till BM, Rahman U, Mack SJ, Koeneman S, Okusanya OT, Evans NR, Grenda TR. PMID: 38879395.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Geographic Variation in the Utilization of Services Surrounding Lung Cancer Resection. Ann Thorac Surg Short Rep. 2024 Sep; 2(3):438-442. Thosani DS, Meredith LT, West R, Till BM, Rahman U, Mack S, Okusanya OT, Evans Iii NR, Grenda TR. PMID: 39790430; PMCID: PMC11708701.
      View in: PubMed   Mentions:
    26. Institutional Experience With Robotic Lobectomy After Neoadjuvant Immunotherapy and Chemotherapy. Ann Thorac Surg Short Rep. 2024 Sep; 2(3):453-457. Mack SJ, Rshaidat H, Ho A, Till BM, Collins ML, Whitehorn GL, Martin J, Jacob JD, Grenda TR, Evans NR, Okusanya OT. PMID: 39790395; PMCID: PMC11708668.
      View in: PubMed   Mentions: 2  
    27. Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies. Haematologica. 2024 03 01; 109(3):835-845. Woolston DW, Lee ND, Shadman M, Latorre-Esteves E, Tee XR, Fredrickson J, Kohrn BF, Ujjani C, Eckel A, Till B, Fang M, Radich J, Bozic I, Risques RA, Yeung CCS. PMID: 37706363; PMCID: PMC10905071.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    28. Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic. Blood Adv. 2024 02 27; 8(4):895-898. Banerjee R, Poh C, Hirayama AV, Gauthier J, Cassaday RD, Shadman M, Cowan AJ, Till BG, Green DJ, Kiem HP, Gopal AK, Maloney DG. PMID: 38197942; PMCID: PMC10875255.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    29. Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Adv. 2024 01 23; 8(2):453-467. Hirayama AV, Kimble EL, Wright JH, Fiorenza S, Gauthier J, Voutsinas JM, Wu Q, Yeung CCS, Gazeau N, Pender BS, Kirchmeier DR, Torkelson A, Chutnik AN, Cassaday RD, Chapuis AG, Green DJ, Kiem HP, Milano F, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ. PMID: 37903325; PMCID: PMC10837185.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    30. Brief Report: Nonmalignant Surgical Resection Among Individuals with Screening-Detected Versus Incidental Lung Nodules. Clin Lung Cancer. 2024 May; 25(3):e129-e132.e4. Till BM, Grenda T, Tidwell T, Wickes B, Shusted C, Ruane B, Okusanya O, Evans NR, Barta JA. PMID: 38185612.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    31. Upper Hemisternotomy Versus Full Sternotomy for Replacement of the Supracoronary Ascending Aorta and Aortic Valve. Innovations (Phila). 2024 Jan-Feb; 19(1):39-45. Shah VN, Binongo J, Wei J, Till BM, King C, McGee J, Plestis KA. PMID: 38087894.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    32. Global Cardiac Surgical Volume and Gaps: Trends, Targets, and Way Forward. Ann Thorac Surg Short Rep. 2024 Jun; 2(2):320-324. Vervoort D, Lee G, Ghandour H, Guetter CR, Adreak N, Till BM, Lin Y. PMID: 39790140; PMCID: PMC11708342.
      View in: PubMed   Mentions: 25  
    33. Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL. Blood Adv. 2023 11 28; 7(22):6990-7005. Liang EC, Albittar A, Huang JJ, Hirayama AV, Kimble EL, Portuguese AJ, Chapuis A, Shadman M, Till BG, Cassaday RD, Milano F, Kiem HP, Riddell SR, Turtle CJ, Maloney DG, Gauthier J. PMID: 37774014; PMCID: PMC10690558.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    34. Access to Guideline Concordant Care for Node-Positive Non-Small Cell Lung Cancer in the United States. Ann Thorac Surg. 2024 03; 117(3):568-575. Collins ML, Mack SJ, Whitehorn GL, Till BM, Grenda TR, Evans NR, Gordon SW, Okusanya OT. PMID: 37995842.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    35. CD8+ chimeric antigen receptor T cells manufactured in absence of CD4+ cells exhibit hypofunctional phenotype. J Immunother Cancer. 2023 11 20; 11(11). Lee SY, Lee DH, Sun W, Cervantes-Contreras F, Basom RS, Wu F, Liu S, Rai R, Mirzaei HR, O'Steen S, Green DJ, Shadman M, Till BG. PMID: 38251688; PMCID: PMC10660840.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    36. Individual- and neighborhood-level characteristics of lung cancer screening participants undergoing telemedicine shared decision making. BMC Health Serv Res. 2023 Oct 30; 23(1):1179. Shusted CS, Juon HS, Ruane B, Till B, Zeigler-Johnson C, McIntire RK, Grenda T, Okusanya O, Evans NR, Kane GC, Barta JA. PMID: 37899430; PMCID: PMC10614340.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    37. Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):e33-e39.e1. Ho C, Gopal AK, Till BG, Shadman M, Lynch RC, Cowan AJ, Wu QV, Voutsinas J, Rasmussen HA, Blue K, Ujjani CS, Cassaday RD, Fromm JR, Fang M, Smith SD. PMID: 37926672; PMCID: PMC10841534.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    38. The Safety of Robotic Pneumonectomy. Ann Thorac Surg Short Rep. 2024 Mar; 2(1):82-87. Mack SJ, Collins ML, Till BM, Whitehorn GL, Martin J, Rshaidat H, Grenda T, Evans NR, Okusanya OT. PMID: 39790278; PMCID: PMC11708279.
      View in: PubMed   Mentions:
    39. Is wedge a dirty word? Demographic and facility-level variables associated with high-quality wedge resection. JTCVS Open. 2023 Sep; 15:481-488. Collins ML, Whitehorn GL, Mack SJ, Till BM, Rshaidat H, Grenda TR, Evans NR, Okusanya OT. PMID: 37808043; PMCID: PMC10556949.
      View in: PubMed   Mentions: 1  
    40. Intraoperative Versus Preoperative Diagnosis of Lung Cancer: Differences in Treatments and Patient Outcomes. Clin Lung Cancer. 2023 12; 24(8):726-732. Mack SJ, Collins ML, Whitehorn GL, Till BM, Grenda TR, Evans NR, Okusanya OT. PMID: 37479586.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    41. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol. 2023 07; 24(7):811-822. Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN, Coffey DG, Tuazon SA, Wood B, Gooley T, Wu VQ, Voutsinas J, Song X, Shadman M, Gauthier J, Chapuis AG, Milano F, Maloney DG, Riddell SR, Green DJ. PMID: 37414012; PMCID: PMC10783021.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCellsCTClinical Trials
    42. Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma. Blood. 2023 05 25; 141(21):2576-2586. Lynch RC, Ujjani CS, Poh C, Warren EH, Smith SD, Shadman M, Till B, Raghunathan VM, Alig S, Alizadeh AA, Gulhane A, Chen DL, Tseng Y, Coye H, Shelby M, Ottemiller S, Keo S, Verni K, Du H, Vandermeer J, Gaston A, Rasmussen H, Martin P, Marzbani E, Voutsinas J, Gopal AK. PMID: 36913694; PMCID: PMC10273164.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    43. Undifferentiated Pleomorphic Sarcoma of the Thoracic Aorta: A Diagnostic and Therapeutic Challenge. Ann Thorac Surg Short Rep. 2023 Jun; 1(2):279-281. Till BM, Java A, King C, Shah VN, Sundaram B, Jiang W, Nooromid MJ, Plestis KA. PMID: 39790317; PMCID: PMC11708736.
      View in: PubMed   Mentions:
    44. Robotic Minimally Invasive Esophagectomy. Thorac Surg Clin. 2023 Feb; 33(1):81-88. Till BM, Grenda TR, Okusanya OT, Evans Iii NR. PMID: 36372536.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    45. Defining risk factors for mortality after emergent hiatal hernia repair in the era of minimally invasive surgery. Am J Surg. 2023 06; 225(6):1056-1061. Collins ML, Mack SJ, Till BM, Whitehorn GL, Tofani C, Chojnacki K, Grenda T, Evans NR, Okusanya OT. PMID: 36653267.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    46. Stop the Bleed: Airway Hemorrhage After Pulmonary Thromboendarterectomy? Ann Thorac Surg. 2023 Jul; 116(1):128-129. Till BM, Tchantchaleishvili V, Rajagopal K. PMID: 36470569.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    47. Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study. J Cell Mol Med. 2022 12; 26(24):5976-5983. Iovino L, Wu QV, Voutsinas J, Panaite L, Mullane E, Lynch RC, Ujjani C, Smith SD, Gopal AK, Till BG, Milano F, Chow V, Gauthier J, Turtle CJ, Maloney DG, Shadman M. PMID: 36453136; PMCID: PMC9753434.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    48. Cessation of Routine Jejunostomy Tube Placement at Time of Minimally Invasive Ivor Lewis Esophagectomy and Impact on Body Mass Index. Semin Thorac Cardiovasc Surg. 2024; 36(1):112-119. Till BM, Mandel J, Unal E, Juckett L, Grenda T, Okusanya O, Palazzo F, Chojnacki K, Evans NR. PMID: 36243237.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    49. Hospital Utilization of Stereotactic Body Radiation Therapy and Rates of Surgical Refusal. Ann Thorac Surg. 2023 02; 115(2):347-354. Till BM, Whitehorn G, Mack SJ, Thosani D, Rahman U, Grenda T, Evans NR, Okusanya OT. PMID: 36027934.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    50. Characteristics of High-Volume Lung Segmentectomy Hospitals: A Propensity Score-Matched Analysis. Clin Lung Cancer. 2022 11; 23(7):600-607. Mack SJ, Till BM, Huang C, Yang CJ, Grenda T, Evans NR, Okusanya O. PMID: 36096972.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    51. Impact of stereotactic body radiation therapy volume on surgical patient selection, short-term survival, and long-term survival in early-stage non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 02; 165(2):471-479. Till BM, Mack S, Whitehorn G, Rahman U, Thosani D, Grenda T, Evans NR, Okusanya O. PMID: 36088141.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    52. Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients. Cancer Immunol Immunother. 2023 Feb; 72(2):437-448. Yuan S, Peng L, Liu Y, Till BG, Yan X, Zhang J, Zhu L, Wang H, Zhang S, Li H, Gao Q, Wang Z. PMID: 35931835; PMCID: PMC10991614.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    53. Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy. Cancer Immunol Immunother. 2023 Feb; 72(2):385-395. An M, Wang W, Zhang J, Till BG, Zhao L, Huang H, Yang Y, Li T, Han L, Zhang X, Qin P, Wang Y, Zhang M, Cui H, Gao Q, Wang Z. PMID: 35907016; PMCID: PMC10992824.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    54. Race is a Risk Factor for the Deferral of Resection and Radiation for Early-Stage Lung Cancer. Clin Lung Cancer. 2022 11; 23(7):e460-e472. Huang CY, Mack S, Grenda TR, Barta JA, Till BM, Evans NR, Okusanya O. PMID: 35989162.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    55. Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies. Front Immunol. 2022; 13:882172. Huang H, Peng L, Zhang B, Till BG, Yang Y, Zhang X, Zhao L, Fu X, Li T, Han L, Qin P, Chen L, Yan X, Liu Y, Wang W, Ye Z, Li H, Gao Q, Wang Z. PMID: 35911715; PMCID: PMC9328170.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    56. Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma. Leuk Lymphoma. 2022 12; 63(12):2918-2922. Panaite L, Wu QV, Voutsinas J, Mullane E, Chow VA, Lynch RC, Ujjani CS, Smith SD, Gopal AK, Poh C, Iovino L, Turtle CJ, Maloney DG, Till BG, Gauthier J, Shadman M. PMID: 35811554.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    57. National trends in pectus excavatum repair: patient age, facility volume, and outcomes. J Thorac Dis. 2022 Apr; 14(4):952-961. Mack SJ, Till BM, Huang C, Thosani D, Rahman U, Grenda T, Evans NR, Okusanya OT. PMID: 35572899; PMCID: PMC9096322.
      View in: PubMed   Mentions: 4  
    58. The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia. Br J Haematol. 2022 05; 197(3):306-309. Ujjani C, Shadman M, Lynch RC, Tu B, Stevenson PA, Grainger C, Zhu H, Hill JA, Huang ML, Nielsen L, Poh C, Sorensen T, Gopal AK, Warren EH, Till BG, Lee S, Gausman D, Smith SD, Gooley T, Greninger A. PMID: 35149986; PMCID: PMC9111753.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    59. Role of fibrosarcoma-induced CD11b+ myeloid cells and tumor necrosis factor-α in B cell responses. Oncogene. 2022 03; 41(10):1434-1444. Wang Z, Liu Y, Peng L, Till B, Liao Y, Yuan S, Yan X, Chen L, Fu Q, Qin Z. PMID: 35034094.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    60. Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study. Clin Lymphoma Myeloma Leuk. 2022 07; 22(7):e443-e451. Palomba ML, Till BG, Park SI, Morschhauser F, Cartron G, Marks R, Shivhare M, Hong WJ, Raval A, Chang AC, Penuel E, Popplewell LL. PMID: 35031227.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    61. Facility-level national trends in racial disparities of surgical therapy for early-stage lung cancer. J Thorac Cardiovasc Surg. 2022 09; 164(3):650-657. Savitch SL, Grenda TR, Yi M, Till B, Mack S, Huang C, Barta JA, Evans NR, Okusanya OT. PMID: 35000683.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    62. Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma. Front Oncol. 2021; 11:728253. Yang Y, Li J, Till BG, Wang J, Zhang B, Wang H, Huang H, Li T, Gao Q, Li H, Wang Z. PMID: 34778042; PMCID: PMC8586206.
      View in: PubMed   Mentions: 2  
    63. Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. Blood Cancer Discov. 2021 Sep; 2(5):408-422. Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, Till BG, Bauer G, Savoldo B. PMID: 34568831; PMCID: PMC8462122.
      View in: PubMed   Mentions: 150     Fields:    Translation:HumansCells
    64. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. Lancet Haematol. 2021 Aug; 8(8):e562-e571. Lynch RC, Cassaday RD, Smith SD, Fromm JR, Cowan AJ, Warren EH, Shadman MS, Shustov A, Till BG, Ujjani CS, Libby EN, Philip M, Coye H, Martino CN, Bhark SL, Morris K, Rasmussen H, Behnia S, Voutsinas J, Gopal AK. PMID: 34329577; PMCID: PMC8457616.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    65. The Robotic Collis Gastroplasty for Paraesophageal Hernia Repair. Innovations (Phila). 2021 Mar-Apr; 16(2):115-116. Till BM, Okusanya OT. PMID: 33818177.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    66. Red blood cell transfusion requirements for patients on extracorporeal membrane oxygenation. Perfusion. 2022 05; 37(4):377-384. Choi MH, Alvarez NH, Till BM, Tsypin Y, Sparks B, Hirose H. PMID: 33657914.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    67. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood. 2021 01 21; 137(3):323-335. Gauthier J, Bezerra ED, Hirayama AV, Fiorenza S, Sheih A, Chou CK, Kimble EL, Pender BS, Hawkins RM, Vakil A, Phi TD, Steinmetz RN, Jamieson AW, Bar M, Cassaday RD, Chapuis AG, Cowan AJ, Green DJ, Kiem HP, Milano F, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ. PMID: 32967009; PMCID: PMC7819764.
      View in: PubMed   Mentions: 105     Fields:    Translation:HumansCellsCTClinical Trials
    68. Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA. Mol Cancer Ther. 2020 12; 19(12):2575-2584. Orozco JJ, Kenoyer AL, Lin Y, O'Steen S, Guel R, Nartea ME, Hernandez AH, Hylarides MD, Fisher DR, Balkin ER, Hamlin DK, Wilbur DS, Orcutt KD, Wittrup KD, Green DJ, Gopal AK, Till BG, Sandmaier B, Press OW, Pagel JM. PMID: 33082277; PMCID: PMC7718432.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    69. Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy. Front Immunol. 2020; 11:563653. Yuan S, Liu Y, Till B, Song Y, Wang Z. PMID: 33162976; PMCID: PMC7584071.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    70. Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. Transplant Cell Ther. 2021 01; 27(1):57.e1-57.e8. Tuazon SA, Cassaday RD, Gooley TA, Sandmaier BM, Holmberg LA, Smith SD, Maloney DG, Till BG, Martin DB, Chow VA, Rajendran JG, Fisher DR, Matesan MC, Lundberg SJ, Green DJ, Pagel JM, Press OW, Gopal AK. PMID: 32980545; PMCID: PMC7990745.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    71. 90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant. 2021 01; 56(1):202-209. Tuazon SA, Sandmaier BM, Gooley TA, Fisher DR, Holmberg LA, Becker PS, Lundberg SJ, Orozco JJ, Gopal AK, Till BG, Coffey DG, Nartea ME, Matesan MC, Pagel JM, Rajendran JG, Press OW, Bensinger WI, Green DJ. PMID: 32710011; PMCID: PMC8328580.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    72. Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade. Br J Haematol. 2020 09; 190(6):e332-e335. Chow VA, Martin PS, Smith SD, Till BG, Graf SA, Edlefsen KL, Hannan LM, Mostaghel EA, Gopal AK. PMID: 32567674.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    73. Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy. Br J Haematol. 2020 06; 189(6):1119-1126. Smith SD, Till BG, Shadman MS, Lynch RC, Cowan AJ, Wu QV, Voutsinas J, Rasmussen HA, Blue K, Ujjani CS, Shustov A, Cassaday RD, Fromm JR, Gopal AK. PMID: 32030732.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCTClinical Trials
    74. Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. Blood Adv. 2019 10 22; 3(20):3062-3069. Shadman M, Gauthier J, Hay KA, Voutsinas JM, Milano F, Li A, Hirayama AV, Sorror ML, Cherian S, Chen X, Cassaday RD, Till BG, Gopal AK, Sandmaier BM, Maloney DG, Turtle CJ. PMID: 31648329; PMCID: PMC6849954.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCells
    75. The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model. Blood. 2019 10 10; 134(15):1247-1256. O'Steen S, Comstock ML, Orozco JJ, Hamlin DK, Wilbur DS, Jones JC, Kenoyer A, Nartea ME, Lin Y, Miller BW, Gooley TA, Tuazon SA, Till BG, Gopal AK, Sandmaier BM, Press OW, Green DJ. PMID: 31395601; PMCID: PMC6788008.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    76. Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. Pract Radiat Oncol. 2020 Jan - Feb; 10(1):44-52. Kim A, Stevenson P, Cassaday RD, Soma L, Fromm JR, Gopal AK, Smith SD, Till B, Lynch RC, Ujjani C, Shadman M, Warren EH, Menon M, Russell K, Tseng YD. PMID: 31585205.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    77. Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Am J Hematol. 2019 08; 94(8):E209-E213. Chow VA, Gopal AK, Maloney DG, Turtle CJ, Smith SD, Ujjani CS, Shadman M, Cassaday RD, Till BG, Tseng YD, Warren EH, Shustov AR, Menon MP, Bhark S, Acharya UH, Mullane E, Hannan LM, Voutsinas JM, Gooley TA, Lynch RC. PMID: 31056762; PMCID: PMC6776079.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCells
    78. Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. Br J Haematol. 2019 07; 186(2):255-262. Geer M, Roberts E, Shango M, Till BG, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, Boonstra PS, Devata S, Wilcox RA, Kaminski MS, Phillips TJ. PMID: 31044423; PMCID: PMC8989046.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    79. Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):390-395. Cooper JP, Khajaviyan S, Smith SD, Maloney DG, Shustov AR, Warren EH, Soma LA, Lynch RC, Ujjani C, Till B, Halpern AB, Gopal AK, Deeg HJ, Scott BL, Shadman M. PMID: 30948330.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    80. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019 04 25; 133(17):1876-1887. Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T, Li D, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Acharya UH, Cassaday RD, Chapuis AG, Dhawale TM, Hendrie PC, Kiem HP, Lynch RC, Ramos J, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ. PMID: 30782611; PMCID: PMC6484391.
      View in: PubMed   Mentions: 211     Fields:    Translation:HumansCTClinical Trials
    81. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019 04 11; 133(15):1652-1663. Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, Gooley TA, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Schoch G, Chapuis AG, Till BG, Kiem HP, Ramos JD, Shadman M, Cassaday RD, Acharya UH, Riddell SR, Maloney DG, Turtle CJ. PMID: 30728140; PMCID: PMC6460418.
      View in: PubMed   Mentions: 225     Fields:    Translation:HumansCTClinical Trials
    82. Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL. Am J Hematol. 2019 04; 94(4):E117-E116. Smith SD, Reddy P, Sokolova A, Chow VA, Lynch RC, Shadman MA, Till BG, Shustov AR, Warren EH, Ujjani CS, Menon MP, Tseng YD, Gopal AK. PMID: 30663774.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    83. Who is pirating medical literature? A bibliometric review of 28 million Sci-Hub downloads. Lancet Glob Health. 2019 01; 7(1):e30-e31. Till BM, Rudolfson N, Saluja S, Gnanaraj J, Samad L, Ljungman D, Shrime M. PMID: 30554757.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    84. Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells. J Cell Physiol. 2019 06; 234(6):9207-9215. Mirzaei HR, Jamali A, Jafarzadeh L, Masoumi E, Alishah K, Fallah Mehrjardi K, Emami SAH, Noorbakhsh F, Till BG, Hadjati J. PMID: 30362586.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    85. Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2019 01; 19(1):48-52. Smith SD, Gandhy S, Gopal AK, Reddy P, Shadman M, Till BG, Lynch RC, Kanan S, Cowan A, Low L, Hill BT. PMID: 30409719.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    86. Predictive and therapeutic biomarkers in chimeric antigen receptor T-cell therapy: A clinical perspective. J Cell Physiol. 2019 05; 234(5):5827-5841. Mirzaei HR, Mirzaei H, Namdar A, Rahmati M, Till BG, Hadjati J. PMID: 30317583.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    87. Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma. Blood Res. 2018 Sep; 53(3):223-226. Greenbaum AM, Green DJ, Holmberg LA, Gooley T, Till BG, Budde LE, Rasmussen H, Press OW, Gopal AK. PMID: 30310789; PMCID: PMC6170297.
      View in: PubMed   Mentions:
    88. Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma. Curr Treat Options Oncol. 2018 07 21; 19(9):45. Till BG. PMID: 30032463.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    89. Combination of Cytokine-Induced Killer Cells and Programmed Cell Death-1 Blockade Works Synergistically to Enhance Therapeutic Efficacy in Metastatic Renal Cell Carcinoma and Non-Small Cell Lung Cancer. Front Immunol. 2018; 9:1513. Wang Z, Liu X, Till B, Sun M, Li X, Gao Q. PMID: 30026742; PMCID: PMC6041387.
      View in: PubMed   Mentions: 16     Fields:    
    90. Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions. J Immunother. 2018 01; 41(1):19-31. Lee SY, Olsen P, Lee DH, Kenoyer AL, Budde LE, O'Steen S, Green DJ, Heimfeld S, Jensen MC, Riddell SR, Press OW, Till BG. PMID: 29176334; PMCID: PMC5759780.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    91. Walking blood banks: an immediate solution to rural India's blood drought. Indian J Med Ethics. 2018 Apr-Jun; 3(2):134-137. Sood R, Raykar N, Till B, Shah H, Roy N. PMID: 29251601.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    92. CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. Blood. 2018 02 08; 131(6):611-620. Green DJ, O'Steen S, Lin Y, Comstock ML, Kenoyer AL, Hamlin DK, Wilbur DS, Fisher DR, Nartea M, Hylarides MD, Gopal AK, Gooley TA, Orozco JJ, Till BG, Orcutt KD, Wittrup KD, Press OW. PMID: 29158362; PMCID: PMC5805491.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    93. From blockchain technology to global health equity: can cryptocurrencies finance universal health coverage? BMJ Glob Health. 2017; 2(4):e000570. Till BM, Peters AW, Afshar S, Meara J. PMID: 29177101; PMCID: PMC5687531.
      View in: PubMed   Mentions: 15     Fields:    
    94. Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma. Biol Blood Marrow Transplant. 2018 02; 24(2):282-287. Tseng YD, Stevenson PA, Cassaday RD, Cowan A, Till BG, Shadman M, Graf SA, Ermoian R, Smith SD, Holmberg LA, Press OW, Gopal AK. PMID: 29061536.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    95. Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):e87-e90. Reddy P, Kanan S, Cowan A, Warren H, Till B, Shadman M, Cassaday R, Press O, Shustov A, Gopal A, Smith SD. PMID: 28870643.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    96. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology. 2017; 6(7):e1331807. Wang Z, Till B, Gao Q. PMID: 28811975; PMCID: PMC5543863.
      View in: PubMed   Mentions: 94     Fields:    
    97. Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. Cancer Res. 2017 07 15; 77(14):3885-3893. O'Steen S, Green DJ, Gopal AK, Orozco JJ, Kenoyer AL, Lin Y, Wilbur DS, Hamlin DK, Fisher DR, Hylarides MD, Gooley TA, Waltman A, Till BG, Press OW. PMID: 28566329; PMCID: PMC5560265.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    98. Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. J Natl Cancer Inst. 2017 01; 109(1). Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, LeBlanc M, Leonard JP, Friedberg JW, Baizer L, Little RF, Kahl BS, Smith MR. PMID: 28040733; PMCID: PMC6059122.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    99. Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers. Cancer Res. 2016 11 15; 76(22):6669-6679. Green DJ, Frayo SL, Lin Y, Hamlin DK, Fisher DR, Frost SH, Kenoyer AL, Hylarides MD, Gopal AK, Gooley TA, Orozco JJ, Till BG, O'Steen S, Orcutt KD, Wilbur DS, Wittrup KD, Press OW. PMID: 27590740; PMCID: PMC5290195.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimals
    100. Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy. Cancer Lett. 2016 10 01; 380(2):413-423. Mirzaei HR, Mirzaei H, Lee SY, Hadjati J, Till BG. PMID: 27392648; PMCID: PMC5003697.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimalsCells
    101. Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer Immunol Res. 2016 06; 4(6):509-19. Rufener GA, Press OW, Olsen P, Lee SY, Jensen MC, Gopal AK, Pender B, Budde LE, Rossow JK, Green DJ, Maloney DG, Riddell SR, Till BG. PMID: 27197068; PMCID: PMC4891234.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    102. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol. 2016 Jan; 172(2):208-18. Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, Floyd JD, DaSilva MA, Moore DF, Pozdnyakova O, Smith SM, LeBlanc M, Friedberg JW. PMID: 26492567; PMCID: PMC4710555.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    103. High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma. Br J Haematol. 2015 Dec; 171(5):788-97. Cassaday RD, Stevenson PA, Gooley TA, Chauncey TR, Pagel JM, Rajendran J, Till BG, Philip M, Orozco JJ, Bensinger WI, Holmberg LA, Shustov AR, Green DJ, Smith SD, Libby EN, Maloney DG, Press OW, Gopal AK. PMID: 26455717; PMCID: PMC4715476.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    104. Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. Biol Blood Marrow Transplant. 2016 Feb; 22(2):380-385. Cowan AJ, Stevenson PA, Cassaday RD, Graf SA, Fromm JR, Wu D, Holmberg LA, Till BG, Chauncey TR, Smith SD, Philip M, Orozco JJ, Shustov AR, Green DJ, Libby EN, Bensinger WI, Shadman M, Maloney DG, Press OW, Gopal AK. PMID: 26348890; PMCID: PMC4716882.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    105. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. Blood. 2015 Mar 26; 125(13):2111-9. Green DJ, Shadman M, Jones JC, Frayo SL, Kenoyer AL, Hylarides MD, Hamlin DK, Wilbur DS, Balkan ER, Lin Y, Miller BW, Frost SH, Gopal AK, Orozco JJ, Gooley TA, Laird KL, Till BG, Bäck T, Sandmaier BM, Pagel JM, Press OW. PMID: 25628467; PMCID: PMC4375108.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    106. Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. Hematol Oncol. 2015 Dec; 33(4):187-91. Onishi M, Graf SA, Holmberg L, Behnia S, Shustov AR, Schiavo K, Philip M, Libby EN, Cassaday RD, Pagel JM, Roden JE, Maloney DG, Green DJ, Till BG, Press OW, Smith SD, Gopal AK. PMID: 25236531; PMCID: PMC4366342.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    107. T-cell immunotherapy: looking forward. Mol Ther. 2014 Sep; 22(9):1564-74. Corrigan-Curay J, Kiem HP, Baltimore D, O'Reilly M, Brentjens RJ, Cooper L, Forman S, Gottschalk S, Greenberg P, Junghans R, Heslop H, Jensen M, Mackall C, June C, Press O, Powell D, Ribas A, Rosenberg S, Sadelain M, Till B, Patterson AP, Jambou RC, Rosenthal E, Gargiulo L, Montgomery M, Kohn DB. PMID: 25186558; PMCID: PMC4435492.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    108. Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity. Leuk Lymphoma. 2015 Jan; 56(1):92-6. Phipps C, Gopal AK, Storer BE, Cassaday RD, Press OW, Till BG, Pagel JM, Palanca-Wessels MC, Philip M, Bensinger WI, Holmberg LA, Shustov AR, Green DJ, Chauncey T, Maloney DG, Libby EN. PMID: 24707941; PMCID: PMC4269586.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    109. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS One. 2013; 8(12):e82742. Budde LE, Berger C, Lin Y, Wang J, Lin X, Frayo SE, Brouns SA, Spencer DM, Till BG, Jensen MC, Riddell SR, Press OW. PMID: 24358223; PMCID: PMC3866194.
      View in: PubMed   Mentions: 123     Fields:    Translation:HumansAnimalsCells
    110. Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013 Sep; 19(9):1403-6. Cassaday RD, Guthrie KA, Budde EL, Thompson L, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Palanca-Wessels MC, Philip M, Bensinger WI, Holmberg LA, Shustov A, Green DJ, Libby EN, Maloney DG, Gopal AK. PMID: 23871782; PMCID: PMC3788600.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    111. Management of mantle cell lymphoma in the elderly. Best Pract Res Clin Haematol. 2012 Jun; 25(2):221-31. Martin P, Smith M, Till B. PMID: 22687458.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    112. Depletion of Tregs for adoptive T-cell therapy using CD44 and CD137 as selection markers. Immunotherapy. 2012 May; 4(5):483-5. Till BG, Press OW. PMID: 22642331; PMCID: PMC3390965.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    113. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012 Apr 26; 119(17):3940-50. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE, Raubitschek A, Forman SJ, Greenberg PD, Riddell SR, Press OW. PMID: 22308288; PMCID: PMC3350361.
      View in: PubMed   Mentions: 299     Fields:    Translation:HumansCells
    114. BCNU-associated pneumonitis: portrait of a toxicity. Leuk Lymphoma. 2012 Jun; 53(6):1019-20. Till BG, Madtes DK. PMID: 22220936.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    115. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol. 2011 Aug 01; 29(22):3023-9. Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg LA, Shustov AR, Green DJ, Maloney DG, Gopal AK. PMID: 21730271; PMCID: PMC3157964.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    116. Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation. J Immunol. 2010 Apr 15; 184(8):4284-94. James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Budde LE, Till BG, Raubitschek AA, Forman SJ, Press OW. PMID: 20220093; PMCID: PMC2896691.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    117. Treatment of lymphoma with adoptively transferred T cells. Expert Opin Biol Ther. 2009 Nov; 9(11):1407-25. Till BG, Press OW. PMID: 19723016; PMCID: PMC2776697.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    118. Response to paclitaxel in adenoid cystic carcinoma of the salivary glands. Head Neck. 2008 Jun; 30(6):810-4. Till BG, Martins RG. PMID: 17979110.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    119. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma. 2008 Jun; 49(6):1062-73. Till BG, Gooley TA, Crawford N, Gopal AK, Maloney DG, Petersdorf SH, Pagel JM, Holmberg L, Bensinger W, Press OW. PMID: 18452065; PMCID: PMC2769072.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    120. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008 Sep 15; 112(6):2261-71. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, Gopal AK, Pagel JM, Lindgren CG, Greenberg PD, Riddell SR, Press OW. PMID: 18509084; PMCID: PMC2532803.
      View in: PubMed   Mentions: 374     Fields:    Translation:HumansCellsCTClinical Trials
    121. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 2008 May 15; 180(10):7028-38. James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ, Press OW. PMID: 18453625; PMCID: PMC2585549.
      View in: PubMed   Mentions: 157     Fields:    Translation:HumansCells
    122. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther. 2007 Aug; 18(8):712-25. Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG, Till B, Raubitschek A, Forman SJ, Qian X, James S, Greenberg P, Riddell S, Press OW. PMID: 17685852.
      View in: PubMed   Mentions: 130     Fields:    Translation:HumansCells
    Brian's Networks
    Concepts (330)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (9)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-40-gb10dcd06 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.